Faculty Opinions recommendation of Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor.

Author(s):  
Florence Duffaud
Cancer ◽  
2011 ◽  
Vol 117 (20) ◽  
pp. 4633-4641 ◽  
Author(s):  
Akira Sawaki ◽  
Toshirou Nishida ◽  
Toshihiko Doi ◽  
Yasuhide Yamada ◽  
Yoshito Komatsu ◽  
...  

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 10015-10015 ◽  
Author(s):  
T. Nishida ◽  
A. Sawaki ◽  
T. Doi ◽  
Y. Yamada ◽  
Y. Komatsu ◽  
...  

Oncology ◽  
2009 ◽  
Vol 76 (5) ◽  
pp. 326-332 ◽  
Author(s):  
Min-Hee Ryu ◽  
Won Ki Kang ◽  
Yung-Jue Bang ◽  
Kyung Hee Lee ◽  
Dong Bok Shin ◽  
...  

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Matteo Borro ◽  
Simone Negrini ◽  
Andrew Long ◽  
Sharon Chinthrajah ◽  
Giuseppe Murdaca

AbstractHistamine is a monoamine synthesized from the amino acid histidine that is well-known for its role in IgE-mediated anaphylaxis but has shown pleiotropic effects on the immune system, especially in order to promote inflammatory responses. H1-receptor antagonist are common drugs used in mild/moderate allergic reactions whereas H2-receptor antagonist are commonly administered in gastric ulcer but showed some properties in allergy too. The EAACI guidelines for diagnosis and treatment of anaphylactic reactions recommend their use as third-line therapy in adjunct to H1-antagonists. The purpose of this article is to produce a complete summary of findings and evidence known so far about the usefulness of H2-receptor antagonist in allergic reactons.


Sign in / Sign up

Export Citation Format

Share Document